Group 1 - The company, Sensong International, announced a capital increase of RMB 330 million for its subsidiary, Shanghai Sensong Pharmaceutical Equipment Engineering Co., Ltd, which will raise the registered capital from RMB 86,309,407 to RMB 99,255,819 [1] - The investment parties include multiple funds, and they have been granted put options to sell their shares back to the company under certain conditions [1] - Following the completion of the subscription, the company's ownership in the target company will decrease from approximately 85.09% to about 73.99% [1] Group 2 - The target company primarily serves industries such as pharmaceuticals, biopharmaceuticals, medical aesthetics, and fast-moving consumer goods, providing core equipment, value-added services, and intelligent factory solutions [2] - The board believes that the transaction will provide funding to expand production capacity and develop upstream and downstream businesses, optimize governance structure, and enhance operational efficiency [2] - The transaction is expected to provide strategic and market resources for the target company's development [2]
森松国际(02155.HK)：授出认沽期权